Results 91 to 100 of about 1,945 (252)
Graph Neural Network‐Based Reinforcement Learning for Decentralized Multi‐Robot Manipulation
Robot arms lifting a large object face a trade‐off: centralized controllers explode in parameters, while decentralized ones cannot coordinate. A GNN resolves this—each arm runs its own network but acts on the full team state, achieving centralized‐level coordination with decentralized execution. Trained across team sizes, a single policy scales to four‐
Tong Chen +3 more
wiley +1 more source
Cancer cells progressively spread over intermediate epithelial‐to‐mesenchymal transition states that cause nuclear enlargement and circular redistribution of filamentous vimentin are classified by deformability cytometry coupled to a multi‐region deep learning model with convolutional feature extraction and attention‐based regional aggregation.
Javad Jarmoshti +8 more
wiley +1 more source
ABSTRACT Enhancing oil recovery (EOR) in mature reservoirs is hindered by high interfacial tension (IFT) and oil‐wet rock formations, especially under harsh, high‐salinity conditions. This study aims to overcome these limitations by synthesizing a novel carbon nanotube nanocomposite covalently grafted with polyethylenimine and non‐covalently ...
Mohamed Abu Shuheil +8 more
wiley +1 more source
Abstract Scholarship on documentation of datasets is increasingly concerned with capturing the context, socio‐technical processes, and decisions shaping data. “Datasheets for datasets” is a recent approach developed by researchers in machine learning that foregrounds transparency and uncovering bias through data documentation.
Emily Maemura, Helena Byrne
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
ABSTRACT Monoclonal antibody (mAb) glycosylation is a critical quality attribute that is difficult to rationally engineer and rapidly assess during cell line development. Here, we investigate whether cell‐surface glycosylation can serve as a surrogate readout of mAb product glycosylation following targeted glycogene engineering in CHO cells.
Cristina Abascal Ruiz +6 more
wiley +1 more source
Accelerating green heterocyclic synthesis: Convergence of AI, automation, and sustainable chemistry
Green heterocyclic synthesis and data‐driven tools such as AI, high‐throughput experimentation, continuous flow, and self‐driving laboratories have developed largely in parallel. This review connects them and asks how green metrics such as E‐factor and PMI might serve as explicit optimization targets rather than post‐hoc measures, toward sustainable ...
Noor Aisyah Ahmad Shah +8 more
wiley +1 more source
Tackling cancer stemness with nanotechnology in the era of precision medicine
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo +9 more
wiley +1 more source
Navigating the Double Edge of Product‐Service Systems: User Behavior, Adoption, and Rebound Effects
ABSTRACT Product‐service systems (PSS) have been considered a promising approach to operationalizing the circular economy. Although many studies have outlined the potential sustainability gains of PSS solutions, it is still unclear what factors drive PSS adoption and how behavioral changes result in rebound effects, undermining their potential ...
Marina Fernandes Aguiar +3 more
wiley +1 more source
ABSTRACT Additive manufacturing (AM) adoption provides numerous benefits, including decentralised production, design flexibility, mass customisation, reduced material waste and lightweight designs. However, AM investment decisions are complex and challenging for manufacturers, and limited knowledge exists about the holistic assessment of relevant costs
Dilupa Nakandala +5 more
wiley +1 more source

